表紙
市場調査レポート

多発性硬化症 : パイプライン製品の分析

Multiple Sclerosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232855
出版日 ページ情報 英文 903 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
多発性硬化症 : パイプライン製品の分析 Multiple Sclerosis - Pipeline Review, H1 2016
出版日: 2016年06月15日 ページ情報: 英文 903 Pages
概要

多発性硬化症(MS)は、自身の免疫系が神経を覆う髄鞘(ミエリン)を攻撃する潜在的な消耗性疾患であり、ミエリンの損傷により、脳、脊髄、その他の部分の間のコミュニケーションが阻害されます。手足の麻痺、筋力低下、複視、霧視、刺痛または疼痛、疲労感、不明瞭発語などの症状があり、年齢、性別、家族歴、一部の感染症などが素因となります。

当レポートでは、世界における多発性硬化症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

多発性硬化症の概要

治療薬の開発

  • 多発性硬化症向けパイプライン製品:概要
  • 多発性硬化症向けパイプライン製品:比較分析

多発性硬化症:開発中の治療薬:企業別

多発性硬化症:開発中の治療薬:大学・研究機関別

多発性硬化症:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

多発性硬化症:開発中の製品:企業別

多発性硬化症:開発中の製品:大学・研究機関別

多発性硬化症:治療薬開発に従事している企業

多発性硬化症:治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 製品概要
  • 作用機序
  • R&Dの進捗

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7962IDB

Summary

Global Markets Direct's, 'Multiple Sclerosis - Pipeline Review, H1 2016', provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
  • The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects
  • The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Multiple Sclerosis Overview
  • Therapeutics Development
  • Multiple Sclerosis - Therapeutics under Development by Companies
  • Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes
  • Multiple Sclerosis - Pipeline Products Glance
  • Multiple Sclerosis - Products under Development by Companies
  • Multiple Sclerosis - Products under Investigation by Universities/Institutes
  • Multiple Sclerosis - Companies Involved in Therapeutics Development
  • Multiple Sclerosis - Therapeutics Assessment
  • Drug Profiles
  • Multiple Sclerosis - Dormant Projects
  • Multiple Sclerosis - Discontinued Products
  • Multiple Sclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Sclerosis, H1 2016
  • Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Multiple Sclerosis - Pipeline by 4D Pharma Plc, H1 2016
  • Multiple Sclerosis - Pipeline by 4SC AG, H1 2016
  • Multiple Sclerosis - Pipeline by AB Science SA, H1 2016
  • Multiple Sclerosis - Pipeline by AbbVie Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Ablynx NV, H1 2016
  • Multiple Sclerosis - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Actelion Ltd, H1 2016
  • Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Aegis Therapeutics, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2016
  • Multiple Sclerosis - Pipeline by AiCuris GmbH & Co. KG, H1 2016
  • Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2016
  • Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Multiple Sclerosis - Pipeline by Antisense Therapeutics Limited, H1 2016
  • Multiple Sclerosis - Pipeline by Antitope Limited, H1 2016
  • Multiple Sclerosis - Pipeline by Aphios Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by Apitope International NV, H1 2016
  • Multiple Sclerosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Argos Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Astellas Pharma Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Athersys, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Axxam SpA, H1 2016
  • Multiple Sclerosis - Pipeline by Baliopharm AG, H1 2016
  • Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Limited, H1 2016
  • Multiple Sclerosis - Pipeline by BioAegis Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by BIOCAD, H1 2016
  • Multiple Sclerosis - Pipeline by Biocon Limited, H1 2016
  • Multiple Sclerosis - Pipeline by Biogen, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Biogenomics Limited, H1 2016
  • Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2016
  • Multiple Sclerosis - Pipeline by Bionature E.A. Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Multiple Sclerosis - Pipeline by Bionovis SA, H1 2016
  • Multiple Sclerosis - Pipeline by Bionure Farma, S.L., H1 2016
  • Multiple Sclerosis - Pipeline by Biovista Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Bird Rock Bio, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Bolder Biotechnology, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016
  • Multiple Sclerosis - Pipeline by C4X Discovery Holdings PLC, H1 2016
  • Multiple Sclerosis - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Celgene Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by Cell Cure Neurosciences, Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Cell2B S.A. , H1 2016
  • Multiple Sclerosis - Pipeline by Cellceutix Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Multiple Sclerosis - Pipeline by Cognosci, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Commence Bio, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Compugen Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Multiple Sclerosis - Pipeline by CuraVac, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Cyxone AB, H1 2016
  • Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2016
  • Multiple Sclerosis - Pipeline by Eisai Co., Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Endece, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by Euroscreen S.A., H1 2016
  • Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H1 2016
  • Multiple Sclerosis - Pipeline by Evotec AG, H1 2016
  • Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Flex Pharma, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2016
  • Multiple Sclerosis - Pipeline by FPRT Bio Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Gemac, H1 2016
  • Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2016
  • Multiple Sclerosis - Pipeline by Genzyme Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Multiple Sclerosis - Pipeline by Glialogix, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Hansa Medical AB, H1 2016
  • Multiple Sclerosis - Pipeline by Hanwha Chemical Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by Harbor Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by HitGen LTD, H1 2016
  • Multiple Sclerosis - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Multiple Sclerosis - Pipeline by Iltoo Pharma, H1 2016
  • Multiple Sclerosis - Pipeline by Immune Response BioPharma, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by ImmuNext, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Immungenetics AG, H1 2016
  • Multiple Sclerosis - Pipeline by InDex Pharmaceuticals AB, H1 2016
  • Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H1 2016
  • Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Io Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Jyant Technologies, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Kadimastem Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by KAHR medical Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Kareus Therapeutics, SA, H1 2016
  • Multiple Sclerosis - Pipeline by Karo Pharma AB, H1 2016
  • Multiple Sclerosis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Kezar Life Sciences, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Kineta, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Multiple Sclerosis - Pipeline by LFB S.A., H1 2016
  • Multiple Sclerosis - Pipeline by Lipocure Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by MacroGenics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by MAKScientific, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by Mallinckrodt Plc, H1 2016
  • Multiple Sclerosis - Pipeline by Mapi Pharma Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by MedAnnex Ltd, H1 2016
  • Multiple Sclerosis - Pipeline by MedDay SA, H1 2016
  • Multiple Sclerosis - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Multiple Sclerosis - Pipeline by MedImmune, LLC, H1 2016
  • Multiple Sclerosis - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Merck KGaA, H1 2016
  • Multiple Sclerosis - Pipeline by Meta-IQ ApS, H1 2016
  • Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by MorphoSys AG, H1 2016
  • Multiple Sclerosis - Pipeline by Neuralstem, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Limited, H1 2016
  • Multiple Sclerosis - Pipeline by Neurotec Pharma SL, H1 2016
  • Multiple Sclerosis - Pipeline by New World Laboratories, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Novartis AG, H1 2016
  • Multiple Sclerosis - Pipeline by NovImmune SA, H1 2016
  • Multiple Sclerosis - Pipeline by Nuevolution AB, H1 2016
  • Multiple Sclerosis - Pipeline by Octapharma AG, H1 2016
  • Multiple Sclerosis - Pipeline by Omeros Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by OncoImmune, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Opexa Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by OPKO Health, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H1 2016
  • Multiple Sclerosis - Pipeline by Parvus Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Peptinov SAS, H1 2016
  • Multiple Sclerosis - Pipeline by Pfenex Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Pfizer Inc., H1 2016
  • Multiple Sclerosis - Pipeline by PharmaEssentia Corporation, H1 2016
  • Multiple Sclerosis - Pipeline by PharmatrophiX, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Pharmaxis Limited, H1 2016
  • Multiple Sclerosis - Pipeline by Pieris Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Plexxikon Inc., H1 2016
  • Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2016
  • Multiple Sclerosis - Pipeline by Prothena Corporation Plc, H1 2016
  • Multiple Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by ReceptoPharm, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Regenesance BV, H1 2016
  • Multiple Sclerosis - Pipeline by Resverlogix Corp., H1 2016
  • Multiple Sclerosis - Pipeline by ReveraGen BioPharma, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by SanBio, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016
  • Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H1 2016
  • Multiple Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Symic Biomedical, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Synthon Holdings BV, H1 2016
  • Multiple Sclerosis - Pipeline by Targazyme, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Teikoku Pharma USA, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Therapix Biosciences Ltd, H1 2016
  • Multiple Sclerosis - Pipeline by TikoMed AB, H1 2016
  • Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2016
  • Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2016
  • Multiple Sclerosis - Pipeline by TxCell SA, H1 2016
  • Multiple Sclerosis - Pipeline by Vaccinex, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2016
  • Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016
  • Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016
  • Multiple Sclerosis - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016
  • Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2016
  • Multiple Sclerosis - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Multiple Sclerosis - Dormant Projects, H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..1), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..2), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..3), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..4), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..5), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..6), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..7), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..8), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..9), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..10), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..11), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..12), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..13), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..14), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..15), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..16), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..17), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..18), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..19), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..20), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..21), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..22), H1 2016
  • Multiple Sclerosis - Dormant Projects (Contd..23), H1 2016
  • Multiple Sclerosis - Discontinued Products, H1 2016
  • Multiple Sclerosis - Discontinued Products (Contd..1), H1 2016
  • Multiple Sclerosis - Discontinued Products (Contd..2), H1 2016
  • Multiple Sclerosis - Discontinued Products (Contd..3), H1 2016
  • Multiple Sclerosis - Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for Multiple Sclerosis, H1 2016
  • Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top